martes, 17 de julio de 2018

U.S. ended pricing plan for cancer drug because of doubts it would work

U.S. ended pricing plan for cancer drug because of doubts it would work

STAT



U.S. ended value-based pricing plan for cancer drug because of doubts it would work

By IKE SWETLITZ @ikeswetlitz
JULY 12, 2018
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)